Tempest Therapeutics (Tempest Therapeutics) Net Current Asset Value : $0.44 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Tempest Therapeutics's net current asset value per share for the quarter that ended in Mar. 2024 was $0.44.

The historical rank and industry rank for Tempest Therapeutics's Net Current Asset Value or its related term are showing as below:

TPST' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.7 Med: 1.72 Max: 8.89
Current: 7.38

During the past 4 years, the highest Price-to-Net-Current-Asset-Value Ratio of Tempest Therapeutics was 8.89. The lowest was 0.70. And the median was 1.72.

TPST's Price-to-Net-Current-Asset-Value is ranked worse than
70.69% of 1027 companies
in the Biotechnology industry
Industry Median: 3.9 vs TPST: 7.38

Tempest Therapeutics Net Current Asset Value Historical Data

The historical data trend for Tempest Therapeutics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tempest Therapeutics Net Current Asset Value Chart

Tempest Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Current Asset Value

-10.83

4.61

0.47

0.70

Tempest Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Current Asset Value	Get a 7-Day Free Trial											-0.16	-0.57	-0.90	0.70	0.44

Competitive Comparison of Tempest Therapeutics's Net Current Asset Value

For the Biotechnology subindustry, Tempest Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tempest Therapeutics's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tempest Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Tempest Therapeutics's Price-to-Net-Current-Asset-Value falls into.

Tempest Therapeutics Net Current Asset Value Calculation

Tempest Therapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Current Asset Value Per Share		(A: Dec. 2023 )
=	(Total Current Assets	-	Total Liabilities	-	Minority Interest	-	Preferred Stock)	/	Shares Outstanding (EOP)
=	(40.363	-	24.835	-	0	-	0)	/	22.0453
=	0.70

Tempest Therapeutics's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2024 is calculated as

	Net Current Asset Value Per Share		(Q: Mar. 2024 )
=	(Total Current Assets	-	Total Liabilities	-	Minority Interest	-	Preferred Stock)	/	Shares Outstanding (EOP)
=	(33.497	-	23.746	-	0	-	0)	/	22.2173
=	0.44

Tempest Therapeutics (NAS:TPST) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.

Tempest Therapeutics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Tempest Therapeutics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Tempest Therapeutics (Tempest Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » Net Current Asset Value

Comparable Companies

Traded in Other Exchanges

3OS:Germany 3OS:Germany

Address

2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005

Website

https://www.tempesttx.com

Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Executives

Justin Trojanowski	officer: Corporate Controller	C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Nicholas Maestas	officer: VP of Strategy and Finance	7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Iv, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Thomas Woiwode	director, 10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas W. Dubensky	director, officer: President	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Samuel Whiting	officer: Chief Medical Officer	C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Rock Springs Capital Llc	10 percent owner	650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202